[Interface between bioinformatics and docking study].
We describe the prospects of bioinformatics for drug discovery and discuss the current status, problems, and future direction of the interface between bioinformatics and docking studies. We also describe our recent work on sequence and structure analysis using the guanidino-modifying enzymes superfamily as a good example.
Shirai
Hiroki
H
Applied Genomics, Molecular Medicine Laboratories, Astellas Pharma Co., Ltd., Tsukuba City, Japan. hiroki.shirai@jp.astellas.com
Kobori
Masato
M
D001665:Binding Sites; D055598:Chemical Phenomena; D002621:Chemistry; D019295:Computational Biology / Q000639:trends; D015195:Drug Design; D011487:Protein Conformation; D011506:Proteins / Q000737:chemistry*
D011506:Proteins